Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients
with various lymphoid malignancies, including indolent and aggressive forms of B-cell non …

The chimeric anti-CD20 monoclonal antibody rituximab has become part of the standard
therapy for patients with non-Hodgkin's lymphoma (NHL). To date, more than 300 000 …

Monoclonal antibody therapy has emerged as an important therapeutic modality for cancer.
Unconjugated antibodies show significant efficacy in the treatment of breast cancer, non …

Based on the favorable safety profile and the independent activity of rituximab in B-cell
lymphoma, we evaluated its efficacy and toxicity after high-dose therapy (HDT) and …

Rituximab (Rituxan®) is a human-mouse chimeric monoclonal antibody that targets the B-
cell CD20 antigen and causes rapid and specific B-cell depletion. Rituximab was approved …

Purpose Minimal residual disease (MRD) is predictive of clinical progression in mantle-cell
lymphoma (MCL). According to the Nordic MCL-2 protocol we prospectively analyzed the …

Background Patients with follicular (FL) or mantle cell lymphoma (MCL) are incurable with
conventional therapy. We investigated the safety and efficacy of rituximab consolidation after …

Rituximab-containing chemotherapy regimens constitute standard first-line therapy for
mantle cell lymphoma (MCL). Since June 2013, 190 patients≥ 18 years of age with MCL in …

Purpose: Cytokine-induced modulation of innate immunity is being explored to enhance the
activity of monoclonal antibodies. Severe combined immunodeficient (SCID) mice engrafted …

BACKGROUND The current study was conducted to analyze the long‐term results of
autologous stem cell transplantation (ASCT) in patients with diffuse mantle cell lymphoma …